Nitric oxide--angiotensin II axis in renal and cardiovascular injury. 2000

A Adam, and L Raij
Department of Veterans Affairs Medical Center and University of Minnesota, Minneapolis 55417, USA.

The knowledge and the information about Renin Angiotensin System and Arginine-Nitric Oxide pathway helped us in understanding more about cardiac, vascular and renal systems, their function, the physiology, and pathophysiology of different diseases that may affect them. The existence of a Nitric Oxide/Angiotensin II axis, brought modification to our ways of thinking with new and more pathophysiological approaches to the treatment of hypertension and end-organ disease. There appears to be a link between hypertension, salt sensitivity, endothelial function and NO-AnglI axis on one side and end organ damage on the other side. Anti-hypertensive agents that can restore endothelial function beside their antihypertensive effect, may be better in preventing or at least slowing end-organ damage.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Adam, and L Raij
November 1998, Nihon Jinzo Gakkai shi,
A Adam, and L Raij
August 1993, Hypertension (Dallas, Tex. : 1979),
A Adam, and L Raij
July 2004, Seminars in nephrology,
A Adam, and L Raij
October 2002, Heart failure reviews,
A Adam, and L Raij
January 2000, Acta physiologica Scandinavica,
A Adam, and L Raij
October 2013, Antioxidants & redox signaling,
A Adam, and L Raij
November 2014, World journal of nephrology,
Copied contents to your clipboard!